Detalhe da pesquisa
1.
A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4).
Ann Oncol
; 28(2): 313-320, 2017 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27803006